NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2006

Primary Completion Date

September 19, 2016

Study Completion Date

September 19, 2016

Conditions

Esophageal Cancer

Interventions

DRUG

Irinotecan

Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8

DRUG

Cisplatin

Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8

PROCEDURE

Radiation

Radiation 50 Gy (weeks 4-9)

PROCEDURE

Surgery

Esophagectomy

DRUG

sunitinib (Sutent)

sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.

Trial Locations (2)

The Ottawa Hospital Regional Cancer Centre, Ottawa

University Health Network (Princess Margaret & Toronto General Hospitals), Toronto